Coagulation, anticoagulation and fibrinolytic system of blood in patients with acute ischemic heart disease and features of changes in combination with diabetes mellitus (cohort prospective study)

Authors

  • Olena Karpenko Bogomolets National Medical University Tarasa Shevchenko blvd., 13, Kyiv, Ukraine, 01601 Medical center “Ok!Clinic+” of International Institute of Clinical Researches LLC Kharkivske highway, 121, Kyiv, Ukraine, 02091, Ukraine https://orcid.org/0000-0002-6530-7543

DOI:

https://doi.org/10.15587/2519-4798.2019.174303

Keywords:

diabetes mellitus, plasma hemostasis, acute ischemic heart disease, thrombotic formation

Abstract

Aim. To evaluate the clotting, anticoagulant and fibrinolytic activity of blood in patients with acute coronary heart disease (ACHD) and to determine the peculiarities of changes when combined with ACHD and DM2.

Materials and methods. 60 persons were diagnosed MI with ST-segment elevation, MI without ST-segment elevation, unstable angina. Among them: 30 patients with ACHD (Group I), 30 patients with ACHD in combination with DM2 (Group II) and 15 practically healthy subjects (control group). The average age of the patients is 64.2±10.01 years, the number of men is 30 (50 %), and women – 30 (50%). Patients were diagnosed with hemostatic parameters in venous blood.

Results. With a general similarity of changes in the anticoagulant system in both groups, attention was drawn to the significant exacerbation of antithrombin activity in patients in group II, which was accompanied by oppression of the PtC system. Thus, the content of ATIII in this group was lower than the control group by 27.8 % (65.5 [54.0; 76.0], p <0.001), and PtC decreased by 37.2 % (0.66 [0, 6, 0,7], p <0,001), whereas in patients of group I anticoagulant activity decreased only at the expense of ATIII-78,0 [74,0; 82.0] versus 90.0 [80.0; 110,0], p<0,01), while the level of PtC did not undergo significant changes. The indicated changes took place against the suppression of fibrinolytic activity in the two groups under study. At the same time, XIIa fibrinolysis appeared to be the most prolonged in group II, namely, 1.6 times in comparison with the same indicator in group І (20.4 [18.5; 23.7] vs. 13.05 [12.6; 13, 7], p<0.001) and 2.6 times different from control (8.0 [7.0; 11.0]; p<0.001).

Conclusions. Changes detected as a result of studying the coagulation linkage of hemostasis in the study groups indicate acceleration of blood coagulation at all stages of coagulation. The presence of DM2 is characterized by a number of changes from the system of hemostasis, which determine the increased risk of thrombotic complications

Author Biography

Olena Karpenko, Bogomolets National Medical University Tarasa Shevchenko blvd., 13, Kyiv, Ukraine, 01601 Medical center “Ok!Clinic+” of International Institute of Clinical Researches LLC Kharkivske highway, 121, Kyiv, Ukraine, 02091

Postgraduate Student

Department of Propaedeutic of Internal Medicine No. 1

References

  1. IDF Diabetes Atlas (2018). Available at: https://www.diabetesatlas.org/
  2. King, R. J., Grant, P. J. (2016). Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. Herz, 41 (3), 184–192. doi: http://doi.org/10.1007/s00059-016-4414-8
  3. Dedov, I. I., Shestakova, M. V. (Eds.) (2016). Sakharnyi diabet 2-go tipa: ot teorii k praktike. Moscow: MIA, 571.
  4. BirhanYilmaz, M., Guray, U., Guray, Y., Altay, H., Demirkan, B., Caldir, V. et. al. (2005). Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coronary Artery Disease, 16 (5), 287–292. doi: http://doi.org/10.1097/00019501-200508000-00005
  5. Maschirow, L., Khalaf, K., Al-Aubaidy, H. A., Jelinek, H. F. (2015). Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes – Biomarkers as a possible tool for early disease detection for rural screening. Clinical Biochemistry, 48 (9), 581–585. doi: http://doi.org/10.1016/j.clinbiochem.2015.02.015
  6. Dedov, I. I., Shestakova, M. V., Vikulova, O. K. (2015). National register of diabetes mellitus in Russian Federation. Diabetes Mellitus, 18 (3), 5–22. doi: http://doi.org/10.14341/dm201535-22
  7. Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R. et. al. (2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115 (1), 114–126. doi: http://doi.org/10.1161/circulationaha.106.179294
  8. Shestakova, M. V., Chazova, I. E., Shestakova, E. A. (2016). Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease. Diabetes Mellitus, 19 (1), 24–29. doi: http://doi.org/10.14341/dm7765
  9. Kondrateva, E. I., Sukhanova, G. A., Litvinova, L. S., Kirienkova, E. V., Kretova, E. I., Zatolokin, P. A. (2011). Vliianie vozrasta i pola na pokazateli koaguliatsionnogo i sosudisto-trombotsitarnogo gemostaza u bolnykh sakharnogo diabeta 2 tipa. Klinicheskaia laboratornaia diagnostika, 8, 41–43.
  10. Kuznik, B. I., Vitkovskiy, Y. A., Zakharova, M. Y., Klyuchereva, N. N., Rodnina, O. S., Solpov, A. V. (2012). Aggregation activity of blood formed elements in patients with type 1 and type 2 diabetes mellitus. Diabetes Mellitus, 15 (2), 49–53. doi: http://doi.org/10.14341/2072-0351-5518
  11. Nelaeva, Iu. V. (2003). Gemostaticheskie izmeneniia u bolnykh sakharnym diabetom 1 tipa s diabeticheskoi nefropatiei. Vozmozhnosti korrektsii alfa-lipoevoi kislotoi. Tiumen.
  12. Petina, M. M., Gorokhovskaia, G. N., Martynov, A. I. (2010). Osobennosti gemostaza u bolnykh sakharnym diabetom 2 tipa v sochetanii s ishemicheskoi bolezniu serdtsa. Meditsinskaia nauka i obrazovanie Urala, 11 (1), 30–36.
  13. Severina, A. S., Shestakova, M. V. (2004). Narushenie sistemy gemostaza u bol'nykh sakharnym diabetom. Diabetes Mellitus, 7 (1), 62–67. doi: http://doi.org/10.14341/2072-0351-5905
  14. Khasanova, Y. V., Nelaeva, A. A., Galkina, A. B., Medvedeva, I. V. (2012). The role of coagulation and inflammation in the development of diabetic nephropathy in patients withdiabetes mellitus type 2. Diabetes Mellitus, 15 (1), 31–34. doi: http://doi.org/10.14341/2072-0351-5976
  15. Jaffa, A. A., Durazo-Arvizu, R., Zheng, D., Lackland, D. T., Srikanth, S., Garvey, W. T., Schmaier, A. H. (2003). Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes. Diabetes, 52 (5), 1215–1221. doi: http://doi.org/10.2337/diabetes.52.5.1215
  16. Heidar, A., Bassam, R., Satish, K., Cohen, M. (2003). Platelets and Antiplatelet Therapy in Patients with Diabetes Mellitus. The Journal of invasive cardiology, 15 (5), 264–269.
  17. Xiangyu, C. H., Fang, L., Hongbo, L. (2017). The Relationship between Type 2 Diabetes and Platelet Indicators. Iranian Journal of Public Health, 46 (9), 1211–1216.
  18. Santilli, F., Simeone, P., Liani, R., Davì, G. (2015). Platelets and diabetes mellitus. Prostaglandins & Other Lipid Mediators, 120, 28–39. doi: http://doi.org/10.1016/j.prostaglandins.2015.05.002

Downloads

Published

2019-08-02

How to Cite

Karpenko, O. (2019). Coagulation, anticoagulation and fibrinolytic system of blood in patients with acute ischemic heart disease and features of changes in combination with diabetes mellitus (cohort prospective study). ScienceRise: Medical Science, (4 (31), 4–8. https://doi.org/10.15587/2519-4798.2019.174303

Issue

No. 4 (31) (2019)

Section

Medical Science

License

Copyright (c) 2019 Olena Karpenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.